Comparative efficacy of novel platinum(IV) compounds with established chemotherapeutic drugs in solid tumour models

Biochemical Pharmacology

Volumn 67, Issue 1, 2004, Pages 17-30

  Hall, Matthew D ^a   Martin, Catherine ^b   Ferguson, David J P ^b   Phillips, Roger M ^c   Hambley, Trevor W ^a   Callaghan, Richard ^b  

^a UNIVERSITY OF SYDNEY   (Australia)

^b UNIVERSITY OF OXFORD   (United Kingdom)

^c UNIVERSITY OF BRADFORD   (United Kingdom)

Author keywords

Apoptosis; Chemotherapy; Platinum drugs; Solid tumour models

Indexed keywords

CHLORAMBUCIL; CISPLATIN; DOXORUBICIN; FLUOROURACIL; PLATINUM DERIVATIVE; VINBLASTINE;

ANTINEOPLASTIC ACTIVITY; APOPTOSIS; ARTICLE; CANCER CHEMOTHERAPY; CANCER INHIBITION; CELL CULTURE; CELL PROLIFERATION; CHROMATIN; COMPARATIVE STUDY; CONTROLLED STUDY; DRUG CYTOTOXICITY; DRUG EFFICACY; DRUG POTENCY; HISTOLOGY; HUMAN; HUMAN CELL; METAPHASE; MORPHOLOGY; PRIORITY JOURNAL; SOLID TUMOR; STATISTICAL SIGNIFICANCE; TUMOR GROWTH;

EID: 0344687262     PISSN: 00062952     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.bcp.2003.07.016     Document Type: Article

References (46)

1. Bosl G.J., Motzer R.J. Testicular germ-cell cancer. New Engl. J. Med. 337(4):1997;242-253.
2. Kelland L.R. New platinum antitumor complexes. Crit. Rev. Oncol. Hematol. 15(3):1993;191-219.
3. Kelland L.R., Murrer B.A., Abel G., Giandomenico C.M., Mistry P., Harrap K.R. Ammine/amine platinum(IV) dicarboxylates: a novel class of platinum complex exhibiting selective cytotoxicity to intrinsically cisplatin-resistant human ovarian carcinoma cell lines. Cancer Res. 52(4):1992;822-828.
4. Andrews P.A., Howell S.B. Cellular pharmacology of cisplatin: perspectives on mechanisms of acquired resistance. Cancer Cells. 2(2):1990;35-43.
5. Kelley S.L., Basu A., Teicher B.A., Hacker M.P., Hamer D.H., Lazo J.S. Overexpression of metallothionein confers resistance to anticancer drugs. Science. 241(4874):1988;1813-1815.
6. Jensen C.B., Grossman S.J., Jollow D.J. Improved method for determination of cellular thiols, disulfides and protein mixed disulfides using HPLC with electrochemical detection. Adv. Exp. Med. Biol. 197:1986;407-413.
7. Ishikawa T., Ali-Osman F. Glutathione-associated cis- diamminedichloroplatinum(II) metabolism and ATP-dependent efflux from leukemia cells. Molecular characterization of glutathione-platinum complex and its biological significance. J. Biol. Chem. 268(27):1993;20116-20125.
8. Petersen L.N., Mamenta E.L., Stevnsner T., Chaney S.G., Bohr V.A. Increased gene specific repair of cisplatin induced interstrand crosslinks in cisplatin resistant cell lines, and studies on carrier ligand specificity. Carcinogenesis. 17(12):1996;2597-2602.
9. Skeel RT. Biologic and pharmacologic basis of cancer chemotherapy. In: Skeel RT, editor. Handbook of cancer chemotherapy. London: Lippincott Williams and Wilkins; 1999. p. 3-20.
10. Jamieson E.R., Lippard S.J. Structure, recognition, and processing of cisplatin-DNA adducts. Chem. Rev. 99(9):1999;2467-2498.
11. Connors T.A., Cleare M.J., Harrap K.R. Structure-activity relationships of the antitumor platinum coordination complexes. Cancer Treat. Rep. 63(9/10):1979;1499-1502.
12. Hall M.D., Hambley T.W. Platinum(IV) antitumour compounds: their bioinorganic chemistry. Coord. Chem. Rev. 232(1/2):2002;49-67.
13. van der Veer J., Peters A.R., Reedijk J. Reaction products from platinum(IV) amine compounds and 5′-GMP are mainly bis(5′-GMP) platinum(II) amine adducts. J. Inorg. Biochem. 26(2):1986;137-142.
14. Eastman A. Glutathione-mediated activation of anticancer platinum(IV) complexes. Biochem. Pharmacol. 36(23):1987;4177-4178.
15. Kido Y., Khokhar A.R., al-Baker S., Siddik Z.H. Modulation of cytotoxicity and cellular pharmacology of 1,2-diaminocyclohexane platinum(IV) complexes mediated by axial and equatorial ligands. Cancer Res. 53(19):1993;4567-4572.
16. Ellis L.T., Er H.M., Hambley T.W. The influence of the axial ligands of a series of platinum(IV) anti-cancer complexes on their reduction to platinum(II) and reaction with DNA. Aust. J. Chem. 48:1995;793-806.
17. Tannock IF, Goldenberg GJ. Drug resistance and experimental chemotherapy. In: Tannock IF, Hill RP, editors. The basic science of oncology. London: McGraw-Hill; 1998. p. 370-91.
18. Sutherland R.M. Cell and environment interactions in tumour microregions: the multicell spheroid model. Science. 240:1988;177-184.
19. Kunz-Schughart L.A., Kreutz M., Knuechel R. Multicellular spheroids: a three-dimensional in vitro culture system to study tumour biology. Int. J. Exp. Pathol. 79(1):1998;1-23.
20. Mueller-Klieser W. Tumor biology and experimental therapeutics. Crit. Rev. Oncol. Hematol. 36(2/3):2000;123-139.
21. Durand R.E., Olive P.L. Resistance of tumor cells to chemo- and radiotherapy modulated by the three-dimensional architecture of solid tumors and spheroids. Methods Cell. Biol. 64:2001;211-233.
22. Kunz-Schughart LA, Meuller-Klieser W. Three-dimensional culture. In: Masters JRW, editor. Animal cell culture. Oxford: Oxford University Press; 2000. p. 123-48.
23. 15N NMR study of the anticancer drug, cis- diamminedichloroplatinum(II), and its hydrolysis and oligomerization products Aust. J. Chem. 34:1981;659-664.
24. Kiernan JA. Histological and histochemical methods. Oxford: Butterworth-Heinemann; 2000.
25. Magaud J.P., Sargent I., Clarke P.J., Ffrench M., Rimokh R., Mason D.Y. Double immunocytochemical labeling of cell and tissue samples with monoclonal antibromodeoxyuridine. J. Histochem. Cytochem. 37(10):1989;1517-1527.
26. De Lean A., Munson P.J., Rodbard D. Simultaneous analysis of families of sigmoidal curves: applications to bioassay, radioligand assay, and physiological dose-response curves. Am. J. Physiol. 235:1978;E97-102.
27. Choi S., Filotto C., Bisanzo M., Delaney S., Lagasee D., Whitworth J.L., Jusko A., Li C., Wood N., Willingham J., Schwenker A., Spaulding K. Reduction and anticancer activity of platinum(IV) complexes. Inorg. Chem. 37:1998;2500-2504.
28. Carlsson J., Nederman T. A method to measure the radio and chemosensitivity of human spheroids. Adv. Exp. Med. Biol. 159:1983;399-417.
29. Inoue S., Ohnuma T., Takaoka K., Suzuki Y., Kaneko M., Safirstein R., Holland J.F. Effects of doxorubicin and cisplatin on multicellular tumor spheroids from human lung cancer. Cancer Drug. Deliv. 4(4):1987;213-224.
30. Knuchel R., Hofstadter F., Jenkins W.E., Masters J.R. Sensitivities of monolayers and spheroids of the human bladder cancer cell line MGH-U1 to the drugs used for intravesical chemotherapy. Cancer Res. 49(6):1989;1397-1401.
31. Evans D.L., Dive C. Effects of cisplatin on the induction of apoptosis in proliferating hepatoma cells and nonproliferating immature thymocytes. Cancer Res. 53(9):1993;2133-2139.
32. Navone A., Raza A. The detection of DNA repair in bromodeoxyuridine vs. thymidine containing DNA of individual cells. Anticancer Res. 7(1):1987;13-16.
33. Kunz-Schughart L.A., Doetsch J., Mueller-Klieser W., Groebe K. Proliferative activity and tumorigenic conversion: impact on cellular metabolism in 3-D culture. Am. J. Physiol. Cell Physiol. 278(4):2000;C765-C780.
34. Chirife A.M., Studzinski G.P. Definition of the cell cycle segment with special sensitivity to vinblastine. Proc. Soc. Exp. Biol. Med. 157(2):1978;206-210.
35. Ellis R.E., Yuan J.Y., Horvitz H.R. Mechanisms and functions of cell death. Annu. Rev. Cell. Biol. 7:1991;663-698.
36. Skladanowski A., Konopa J. Adriamycin and daunomycin induce programmed cell death (apoptosis) in tumour cells. Biochem. Pharmacol. 46(3):1993;375-382.
37. Wyllie A.H., Beattie G.J., Hargreaves A.D. Chromatin changes in apoptosis. Histochem. J. 13(4):1981;681-692.
38. Wyllie A.H., Morris R.G., Smith A.L., Dunlop D. Chromatin cleavage in apoptosis: association with condensed chromatin morphology and dependence on macromolecular synthesis. J. Pathol. 142(1):1984;67-77.
39. Tunggal J.K., Cowan D.S., Shaikh H., Tannock I.F. Penetration of anticancer drugs through solid tissue: a factor that limits the effectiveness of chemotherapy for solid tumors. Clin. Cancer Res. 5(6):1999;1583-1586.
40. Phillips R.M., Loadman P.M., Cronin B.P. Evaluation of a novel in vitro assay for assessing drug penetration into avascular regions of tumours. Br. J. Cancer. 77(12):1998;2112-2119.
41. Kerr D.J., Wheldon T.E., Hydns S., Kaye S.B. Cytotoxic drug penetration studies in multicellular tumour spheroids. Xenobiotica. 18(6):1988;641-648.
42. Wartenberg M., Hescheler J., Acker H., Diedershagen H., Sauer H. Doxorubicin distribution in multicellular prostate cancer spheroids evaluated by confocal laser scanning microscopy and the "optical probe technique" Cytometry. 31(2):1998;137-145.
43. Barry M.A., Behnke C.A., Eastman A. Activation of programmed cell death (apoptosis) by cisplatin, other anticancer drugs, toxins and hyperthermia. Biochem. Pharmacol. 40(10):1990;2353-2362.
44. Eastman A. Activation of programmed cell death by anticancer agents: cisplatin as a model system. Cancer Cells. 2(8/9):1990;275-280.
45. Erlichman C., Vidgen D., Wu A. Cytotoxicity of cisplatin and cisdiammine-1,1-cyclobutane dicarboxylate in MGH-U1 cells grown as monolayers, spheroids, and xenografts. J. Natl. Cancer Inst. 75(3):1985;499-505.
46. Chu G. Cellular responses to cisplatin. The roles of DNA-binding proteins and DNA repair. J. Biol. Chem. 269(2):1994;787-790.